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CONCLUSION
There was no significant differences of 
plasma angiotensin II levels in women  with type 2 
diabetes mellitus women who also have 
hypertension when compared to the ones without 
hypertension. However the findings of the present 
study provide alarming evidences for health 
professionals and policy makers about the high 
prevalence of high plasma angiotensin II in type 2 
diabetes mellitus in our population. Preventive and 
treatment strategies, notably in women, are urgently 
needed to prevent and promote healthy lifestyle 
habits.
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ABSTRACT
Background. Tumor Necrosis Factor-α 
(TNF-α), a pro-inflammatory cytokine produced by 
monocyte is increased in osteoarthritis synovial 
fluid. Curcuminoid from Curcuma domestica Val. 
suppresses the secretion of TNF-α. 
Objective. The purpose of this study was to 
investigate the suppression effect of curcuminoid 
from Curcuma domestica Val on synovial fluid 
monocyte's TNF-α secretion compared to diclofenac 
sodium in knee osteoarthritis 
Methods. A prospective randomized open 
end blinded evaluation (PROBE) method was 
applied. Subjects were patients with knee 
osteoarthritis visiting Rheumatology Clinic Dr. 
Sardjito Hospital and Wirosaban Hospital 
Yogyakarta. Curcuminoid 30 mg three times daily or 
diclofenac sodium 25 mg three times daily were 
administered for 4 weeks. The level of TNF-α 
secreted by synovial fluid's monocytes were 
measured by ELISA before and after treatment. 
Results. A total of 80 subjects were enrolled, 
39 subjects on curcuminoid treatment groups and 41 
subjects on diclofenac sodium group. Seven subjects 
were dropped out, 5 from the curcuminoid group and 
2 from the diclofenac sodium group. There was a 
significant decrement of TNF-α level during 4 weeks 
treatment in both groups (p< 0.001 respectively). 
There was no significant difference on TNF-α levels 
between groups (p= 0,237), neither in 50% 
decrement of TNF-α levels (p= 518).
Conclusion. The effect of curcuminoid in 
decreasing TNF- α level on patients with 
osteoarthritis is similar with sodium diclofenac.
Keywords: osteoarthritis-monocyte-TNF-α-
curcuminoid-diclofenac sodium
INTRODUCTION 
Osteoarthritis (OA) is a degenerative joint 
disease that has been related to damage of the joint's 
cartilage. The manifestations of osteoarthritis such 
as changes in morphology, biochemistry, molecular 
and biomedical aspects of cells and matrixes result 
in fibrillation, ulceration, thinning of joint's 
cartilage, sclerosis and formation of osteophyte and 
1  bone cyst .
The prevalence of knee osteoarthritis from 
radiologic examination in Indonesia is high, 
approximately 15.5% in man and 12.7% in woman. 
Due to the high level of prevalence and its chronic 
progressive characteristic, osteoarthritis has been 
contributing a big impact, socially and 
economically, in developed countries as well as in 
developing countries. In Indonesia, the estimated 
numbers of elderly who suffers from disability due 
2to OA, is around 1 until 2 million people . 
The role of cytokines in OA contributes 
major effects to the incident and disease 
progressiveness. Tumor necrosis factor-α (TNF-α) 
and interleukin-1 (IL-1) has been suspected to have 
responsible as mediators for chondrocyte response 
3in this joint disease . In osteoarthritis, IL-1 and TNF-
α activate the degradating enzymes such as 
metalloproteinase, collagenase, gelatinase and 
aggrecanase that can generate the inflammatory 
4responses in the joint . Both cytokines, IL-1β and 
TNF-α, has been shown to play roles in cartilage 
destruction and inflammatory process'. An 
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increment of  IL-1 β and TNF-α has been found in 
5synovial fluid and cartilage of patients with OA . 
Osteoarthritis management aimed to control 
symptoms especially in joint pain of the bone, 
reduce disability and joint damage progression, 
enabling patient to continue their living without 
resistance in function and minimum social impacts. 
Non-steroidal anti inflammatory drugs (NSAIDs) 
have an analgesic, anti-pyretic and anti-
inflammatory effects. Its mechanism  targets the 
cyclooxygenase (COX) enzyme. One of the NSAID 
which has often been used in daily practices is 
6,7diclofenac sodium .
Curcuminoid is secondary metabolite 
derived from Curcuma domestica Val. and 
temulawak which has been used as flavor and herbal 
remedies component. Curcuminoid has been known 
for their activity in inflammatory process and 
elimination of mild bone pain and low side effects to 
8the gastro intestinal tract .
The aim of the study is to investigate the 
effect(s) of curcuminoid from Curcuma domestica 
Val. compared to diclofenac sodium in its ability to 
suppress the secretion of TNF-α by synovial fluid 
monocytes of the knee affected by osteoarthritis. 
SUBJECTS AND METHOD 
This research was established in a clinical 
trial entitled as the Prospective Randomized Open 
And Blinded Evaluation = PROBE. The research 
was enrolled from May to September 2007 in 
Rheumatology Clinic, Dr. Sardjito Hospital 
The inclusion criteria includes patients who 
suffer knee OA that was diagnosed based on ACR 
1986 criteria, have synovial fluid sample from the 
knee joint with minimum volume of 2 cc, agreed to 
participate in this research by signing informed 
consent. Exclusion criteria includes impairments in 
liver function (increment of serum transaminase 
enzymes more than 2 times of the normal of upper 
limit) and kidney function (serum creatinin > 2 
mg/dl), has history of peptic ulceration or duodenum 
ulceration, in anticoagulant drug(s), had undergone 
surgery on the affected knee, had received 
corticosteroid injection or viscous supplement at the 
knee joint in the past 3 month, or if there is any 
contraindication for intra-articular injection. Thirty 
subjects were included in each group. 
Methods. The participants received 
information and explanation about the study 
purposes and objectives. Patients who had been 
using analgesic drug were obliged to stop the 
consumption of the drug for at least 7 days. 
Randomization was done on 6 block. The subjects 
were divided into 2 groups. The synovial fluids of 
the knee joint were measured to investigate the level 
of TNF-α. The subject in the treatment group were 
given capsules containing 30 mg curcuminoid from 
Curcuma domestica Val. three time 1 capsule daily 
and the subject in the control group were treated with 
capsules containing 25 mg of diclofenac sodium 
three time 1 capsule daily. After 4 weeks treatment, 
measurement of the synovial fluid in the knee joint 
was repeated to investigate the level of TNF-α rate 
secreted by monocyte in synovial fluid. The 
measurement of the ability of synovial fluid 
monocytes to secrete TNF-α were accomplished by 
monocytes cell culture in a culture media. The 
ELISA method was performed to assess the TNF-α 
level in culture media before starting and after 4 
weeks treatment. 
Data of the study subjects is presented in 
means and standard deviations. The mean 
differences of TNF-α level in the curcuminoid group 
and the natrium diclofenac group was analyzed with 
t-test where 95% confidence interval and p value 
<0.05 was considered as significant. If pre-
requisites terms and conditions for the application of 
t-test were not fulfilled, then the Mann-Whitney test 
was used. Changes in TNF-α rate before and after 
therapy was analyzed with paired t-test where 95% 
confidence interval with p value <0.05 was 
considered as significant. When criterias for paired 
t-test was not fulfilled, a Wilcoxon signed rank test 
was applied. 
RESULTS 
There were 80 subjects who fulfilled 
inclusion without exclusion criteria. Five subjects 
from curcuminoid group were dropout: one subject 
was hospitalized because of urinary tract infection, 
one subject was hospitalized because of chronic 
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Table 2 showed the age average of 
curcuminoid group is 64.05±8.83 years while in 
diclofenac is 64.56±8.86 years. The age between 
both groups is not significantly different (p= 0.700). 
The average history of osteoarthritis for 
curcuminoid group is 2.94±3.48 years while in 
Table 1. Data base of subjects with normal distribution 
Variable  Curcuminoid 
group  
(n=39)  
Diclofenac  
group  
(n=41)  
95% CI  P  
Sex  
• Female  
• Male  
 
24 
15  
 
29  
24  
 
    0.385* 
Weight (kg)  62.91±11.38  63.28±11.64  -5.50-4.76  0.886** 
Height (cm)  154.36±7.37  154.78±7.67  -3.77-2.93  0.803** 
2Abbreviation : * X -test ; ** t-test ; CI: Confident Interval; SD : Standard Deviation
Tables 1 showed the data of subjects. In the 
curcuminoid group the proportion of female was 
61.54% while in the group of diclofenac sodium the 
proportion of female was 70.73%. The difference of 
body weight between both groups was not 
statistically significant with p=0.385. The body 
weight of the curcuminoid group was 62.91±11.38 
Table 2. Data base of subjects without normal distribution 
kg while in diclofenac sodium group was 
63.28±11.64 kg. The difference of the weight 
average between both group was not statistically 
significant (p= 0.886). The average of height in 
curcuminoid group was 154.36±7.37 cm while in 
diclofenac group was 154.78±7.67 cm with no 
significant difference. 
Variable  Curcuminoid 
group  
(n=39)  
mean±SD  
(median)  
Diclofenac  
group  
(n=41)  
mean±SD  
(median)  
P  
Age (years)  64.05±8.83  
(66)  
64.56±8.86  
(64)  
0.700*  
History of OA (years)  2.94±3.48  
(2.00)  
3.40±2.38  
(3.00)  
0.052*  
TNF-a (pg/ml) 
 
53.95±61.35  
(37.85) 
69.35±113.14  
(26.01) 
0.192*  
Abbreviation : *Mann-Whitney test; SD: Standard Deviation 
diclofenac group is 3.40±2.48 years (p=0.052). The 
average level of TNF-α before treatment in 
curcuminoid group is 53.95±61.35 pg/ml while in 
diclofenac group the level is 69.35±113.14 pg/ml 
(p= 0.192). 
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obstruction pulmonary disease, one subject had joint 
swelling and pain, one subject had hematuria 
because of bladder mass, one subject stopped the 
therapy without any reason. From diclofenac 
sodium group there was one subject stopped the 
therapy because of heart burn after 1 week therapy 
and one subject has no synovial fluid in the end of the 
study. 
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Table 3 showed the averages and the median of TNF-α level before and after 4 weeks therapy. The 
decreasing of TNF-α level in the curcuminoid group is from 52.92±65.43 pg/ml to 25.84±37.66 pg/ml. The 
decreasing of TNF-α level in diclofenac group is from 55.28±95.94 pg/ml to 19.05±18.61 pg/ml. The data is 
not in normal distribution, causing Wilcoxon signed ranks test to be used. The difference before and after 
treatment was significant (p<0,001). 
Table 4. Mean of difference between TNF- α level before and after 4 weeks treatment
Table 3. Level of TNF-α before and after 4 weeks treatment
TNF-α (pg/ml)  
Before treatment   
                                                          Mean±SD  
                                                           (Median)  
TNF-α (pg/ml)  
After treatment  
Mean±SD  
(Median)  
P  
Curcuminoid group  
(n=34)  
54.92±65.43  
( 36.06)  
25.84±37.66  
(11.27)  
p<0.001*
Natrium diklofenak group  
(n=39) 
55.28±95.94  
(24.90) 
19.05±18.61  
(11.04) 
p<0.001*
Abbreviation : *Wilcoxon signed ranks test; TNF-α : Tumor Necrosis Factor-α; 
                SD : Standard Deviation
Paired t-test  95% CI  
Curcuminoid group  
(n=34)  
0.013  6.6 –  51.6  
Diclofenac group  
(n=39)  
0.017  6.9 –  65.6  
Abbreviation: CI: Confidential Interval 
Table 4 showed the mean of difference of decreasing TNF-α level before and after 4 weeks treatment 
for curcuminoid group and diclofenac group. The mean of difference of decreasing TNF-α level before and 
after treatment for the curcuminoid group was statistically significant (p=0.013; 95% CI 6.6 – 51.6) while in 
diclofenac group it is also statistically significant (p=0.017; 95% CI 6.9 – 65.6).
Table 5. Mean of difference of TNF-α level before and after 4 weeks treatment
Variable  Curcuminoid 
group  
(n=34)  
mean±SD  
(median)  
diclofenac  
group  
(n=39)  
mean±SD  
(median)  
P  
Mean of difference of TNF-α level 
before and after 4
 
weeks treatment 
(pg/ml)  
29.07±64.42  
(19.97)  
36.22±90.66  
(12.94)  
0.237*  
Abbreviation : * Mann-Whitney test; TNF: Tumor Necrosis Factor; SD: Standard Deviation 
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Tables 6 showed no significant difference 
of 50% decreasing of TNF-α level between both 
group (p= 0518).
DISCUSSION 
Diclofenac sodium inhibit the NFκβ in 
inducing monocyte to produce TNF-α. As 
unselective  COX-2 inhibitor diclofenac is able to 
inhibit the activation of COX-2. Diclofenac also 
able to block the peroxisome proliferators activated 
9receptor-γ (PPAR-γ) . Existence of these inhibition 
activity, diclofenac is able to suppress the 
production of TNF-α. This research showed the 
decreasing of TNF-α level in both treatment group. 
Decreasing the mean of difference of TNF-α level 
was not significant different between the 
curcuminoid group and diclofenac group, meaning 
their activities are comparable.
The reason of dropout in curcuminoid 
group looked not correlated to the effect of 
curcuminoid, except for the joint swelling and the 
pain.
Kertia et al (2005) have run the research 
regarding the influence of combination of 
curcuminoid from Curcuma domestica Val and 
essential oil of temulawak rhizome to the leucocyte 
count in synovial fluid of patients with osteoarthritis 
compared to piroxicam at random blind. The result 
showed that both of drugs suppressed the leucocyte 
10count significantly and comparably . Chan (1995) 
has run the in vitro research and proved that the 
11curcuminoid can reduce the TNF-α production . 
Table 5 showed the mean of difference of TNF-α in curcuminoid group before and after 4 weeks 
treatment is 29.07±64.42 pg/ml while in the diclofenac group is 36.22±90.66 pg/ml. The Mann-Whitney 
analysis showed no significant difference between decreasing of TNF-α level between the curcuminoid group 
and diclofenac group with p=0.237.
Table 6. Fifty percent decreasing of TNF-α level between groups
Variabel  Curcuminoid 
goup  
(n=34)  
Diclofenac  
group  
 (n=39)  
P  
50% decreasing of TNF-α level  20  20  0.518*  
Less than 50% decreasing of TNF-α 
level 
14  19  
2Abbreviation: * X -test 
This research also showed that 50% decreasing of 
TNF-α level was not significantly differ between 
both groups. 
CONCLUSION 
The effect of curcuminoid in decreasing 
TNF- α level on patients with osteoarthritis is 
similar with sodium diclofenac.
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INTRODUCTION
The word sepsis is derived from the Greek 
term for rotten or “to make putrid”. Sepsis, defined 
as the systemic host response to microorganisms in 
previously sterile tissues, is a syndrome related to 
severe infections and is characterized by end-organ 
dysfunction away from the primary site of infection. 
To meet the definition of sepsis, patients need to 
satisfy at least two of the Systemic Inflammatory 
Response Syndrome (SIRS) criteria in association 
with having a suspected or confirmed infection. The 
severity and mortality increase when this condition 
is complicated by predefined organ dysfunction 
(severe sepsis) and cardiovascular collapse (septic 
shock). The normal host response to infection is 
complex, aiming to both identify and control 
pathogen invasion and start immediate tissue repair. 
Both the cellular and humoral immune systems are 
activated, giving rise to anti-inflammatory and 
proinflammatory responses. Exacerbating these 
mechanisms can cause a chain of events that leads to 
sepsis, promoting massive liberation of mediators 
1and the progression of multiple organ dysfunction .
Sepsis remains a critical problem with 
significant morbidity and mortality even in the 
modern era of critical care management. Despite 
intense efforts, sepsis remains a serious clinical 
problem and still associated with a high mortality 
rate. Septic shock and sequential multiple organ 
failure/dysfunction syndrome (MOF/MODS) 
correlate with poor outcome, and septic shock is the 
most common cause of death in intensive care units. 
A recent review by Angus et al estimated the 1995 
incidence of sepsis in the United States to be 751,000 
cases, resulting in 215,000 deaths. The average cost 
per case of sepsis was $22,100 with total costs of 
$16.7 billion nationally. A more recent analysis of 
hospital records indicates that the total number of 
patients who are dying is actually increasing. This 
study also confirmed the work of Angus et al that the 
incidence of sepsis is increasing and projected to 
continue to grow as the population ages. These 
studies concluded that “severe sepsis is a common, 
expensive, and frequently fatal condition, with as 
many deaths annually as those from acute 
2,3myocardial infarction .
The immunological cascade resulting in the 
sepsis response can be initiated by tissue injury, 
ischemia reperfusion injury, gram-positive 
organisms, and fungi as well as gram-negative 
organisms and their constituent endotoxin. The 
sepsis response may begin with an infectious nidus, 
which may either invade the bloodstream, leading to 
dissemination and positive blood cultures, or 
proliferate locally and release various microbial 
3products into the bloodstream .
Multiple derangements exist in sepsis 
involving several different organs and systems, 
although controversies exist over their individual 
contribution to the disease process. Septic patients 
have substantial, life-threatening alterations in their 
coagulation system. Previously, it was believed that 
sepsis merely represented an exaggerated, 
hyperinflammatory response with patients dying 
from inflammation-induced organ injury. More 
recent data indicate that substantial heterogeneity 
exists in septic patients' inflammatory response, 
with some appearing immuno-stimulated, whereas 
others appear suppressed. Cellular changes continue 
the theme of heterogeneity. Some cells work too well 
such as neutrophils that remain activated for an 
extended time. Other cellular changes become 
accelerated in a detrimental fashion including 
2lymphocyte apoptosis . 
The role that apoptosis plays in sepsis 
syndromes and in the development of CARS and 
MODS has not been adequately explored, but there 
is rapidly developing evidence to suggest that 
increased apoptotic processes may play a 
determining role in the outcome to sepsis 
